The FDA warning for citalopram thus appeared to be at odds with previous research findings, and it recommended a substantial change in routine clinical practice. We therefore sought to examine whether the relationship between citalopram dosage and adverse events was consistent with the FDA warnings under real-world conditions. In our study (3), we assessed whether among patients treated for depression in the Veterans Health Administration, the largest national integrated health care system in the country, we could find an increased incidence of abnormal heart rhythms (including torsade de pointes) or mortality associated with high-dosage citalopram. Our study of more than 600,000 patients taking citalopram found no elevated risks for either ventricular arrhythmias or all-cause, cardiac, or noncardiac mortality associated with daily doses above 40 mg compared with lower doses. Instead, higher doses were associated with fewer adverse outcomes. Our study is not alone in finding no significant association between treatment with citalopram and cardiac risks. Recent research has confirmed that QT prolongation with the use of citalopram and other antidepressants has been modest (4).